AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05273840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ivital Control
Description: Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
Study NCT05273840 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle intervention
Description: Patients will receive lifestyle interventions.
Study NCT05742698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
Study NCT05742698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
Study NCT05044884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise training
Description: 1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles.
Study NCT05613478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
Study NCT05613478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
Study NCT05613478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: Radical surgery
Study NCT05613478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery
Study NCT05613478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative TACE treatment
Description: TACE treatment before preoperative camrelizumab combined with apatinib mesylate
Study NCT05613478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q3w (at least 6 cycles) after radical surgery
Study NCT05613478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate is administered at 250mg, qd (at least 6 cycles) after radical surgery
Study NCT06270810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
Study NCT06270810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing non-Exercise Physical Activity
Description: Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
Study NCT05711784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules
Description: Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Study NCT05711784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules
Description: Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Study NCT05711784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Resistant Dextrin) Capsules
Description: Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
Study NCT05096793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta alanine
Description: On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
Study NCT06556537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face-to-face and video-assisted training
Description: During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes.
Study NCT05341310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHDCoach
Description: ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
Study NCT05341310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic
Study NCT05341310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic
Study NCT04730713 — intervention group
Intervention type: DEVICE
Intervention: The morphology and parameters of cranial ultrasound spectrum based on cerebral artery
Description: Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
Study NCT04746131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM0306
Description: IMM0306 is an bi-specific antibody
Study NCT06407258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEPAC
Description: 6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs.
Study NCT04675359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint
Description: Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
Study NCT04594187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
Study NCT04594187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
Study NCT04854395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcain 5 mg/ml
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
Study NCT04594187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04594187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04594187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo nodal radiation therapy
Study NCT04638322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFT Group
Description: An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
Study NCT05044884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training
Description: 1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles
Study NCT06105320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCHF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%
Study NCT06105320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HCLF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%
Study NCT06064812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1802
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.
Study NCT06064812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbocilib
Description: The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days.
Study NCT04808882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin, Low dose prophylactic anticoagulation
Description: Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.
Study NCT04808882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin, High dose prophylactic anticoagulation
Description: Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.
Study NCT04808882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin,Therapeutic anticoagulation
Description: Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.
Study NCT05192759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study NCT05212064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen nasal cannula therapy
Description: Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
Study NCT05212064 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: nasal cannula oxygen therapy
Description: Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
Study NCT06505564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Description: In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
Study NCT05618366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
Study NCT05618366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800mg taken orally, twice daily.
Study NCT05519202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Oxaliplatin, Penpulimab
Description: S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
Study NCT05122195 — intervention group
Intervention type: OTHER
Intervention: Compression therapy
Description: Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
Study NCT06020261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training
Description: developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
Study NCT05568862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound, Urodynamic assessment.
Description: The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
Study NCT05568862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic assessment.
Description: A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
Study NCT04722003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
Study NCT04722003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.